Issue Date: May 15, 2017
Patient dies in Kite drug trial
In a development with an uncomfortable parallel, Kite Pharma reported a death in a clinical trial of a cancer immunotherapy based on chimeric antigen receptor T-cell technology, commonly known as CAR-T therapy.
CAR-T therapies are created by removing T cells from a patient, engineering them to hunt a specific kind of cancer cell, growing them in a bioreactor, and then returning them to the patient.
. . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society